Physician profile
Marina Roytman
NPI 1770521452
$164,582.51
in general payments reported to CMS, 2019-2025
18 companies · $94K in 2025
The $94K reported for 2025 was more than what 91% of Hepatology providers received nationally (typical 2025 total: $981).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,676 · 2020: $508 · 2021: $3,358 · 2022: $9,417 · 2023: $7,444 · 2024: $46K · 2025: $94K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $91K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $20K · Consulting Fee: $18K · Travel and Lodging: $13K · Food and Beverage: $6,383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,751.75 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $20,000.00 |
| Consulting Fee | $17,592.50 |
| Travel and Lodging | $12,895.95 |
| Food and Beverage | $6,383.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $64,378.49 | 2019-2025 | Epclusa, Vemlidy, Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58,178.81 | 2021-2025 | Xifaxan |
| Madrigal Pharmaceuticals | $32,310.28 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $3,247.11 | 2020-2025 | Mavyret |
| Ipsen Biopharmaceuticals, INC | $2,963.33 | 2025 | Iqirvo |
| Novo Nordisk INC | $2,292.70 | 2022-2024 | |
| Intercept Pharmaceuticals, INC. | $612.89 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $117.70 | 2023 | Xifaxan |
| Lilly USA, LLC | $98.52 | 2022-2023 | Mounjaro |
| Cook Medical LLC | $96.83 | 2025 | Echotip Insight |
| Dova Pharmaceuticals | $94.44 | 2020 | |
| Mallinckrodt Hospital Products INC. | $51.02 | 2023 | Terlivaz |
| Foundation Medicine, INC. | $50.33 | 2020 | |
| Exact Sciences Corporation | $41.63 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $28.60 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.83 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Roytman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.